rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

AngioDynamics, Inc.

ANGO · Nasdaq

Health CareMedical DevicesNot moving yet

ANGO stood above a rising 150-day average in 28 of the last 52 weekly readings, and has been out of that trend for the last 2 weeks. It is 13.2% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 2
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$118K
Insider sales, 12 months
$688K
Officials’ trades on record
6
Institutions holding
152 (+16)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 28 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$655K$0$206KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

6 disclosed lines: House 6, Senate 0, executive 0; 2 people.

WhoDidAmountTraded
Debbie Wasserman Schultz House: U.S. House ClerkFL25solddependent child$2k20 Oct 2025filed 24 Oct 2025
Debbie Wasserman Schultz House: U.S. House ClerkFL25sold$1k–$15k16 Jul 2025filed 25 Jul 2025
Debbie Wasserman Schultz House: U.S. House ClerkFL25boughtdependent child$1k–$15k27 Jun 2025filed 25 Jul 2025
Debbie Wasserman Schultz House: U.S. House ClerkFL23sold$1k–$15k8 Nov 2016filed 25 Dec 2016
Debbie Wasserman Schultz House: U.S. House ClerkFL23bought$1k–$15k27 Apr 2016filed 6 Jul 2016
Debbie Wasserman Schultz House: U.S. House ClerkFL23boughtdependent child$1k–$15k27 Apr 2016filed 6 Jul 2016

Insiders

Buy orders, 12 months1
Sale orders, 12 months1
Buyers · sellers1 · 1
WhoDidSharesTraded
Warren Nighan, Jr.SVP Quality and Regulatorysold23,370at $14.7230 Jul 2026filed 31 Jul 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders152+16 on the quarter
New · exited31 · 14
Reported value$490.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20263,803,232$49.5M+117,328+3.2%
Point72 Asset Management, L.P.reduced · filed 14 Aug 20263,062,517$39.8M-119,312−3.7%
SYSTEMATIC FINANCIAL MANAGEMENT LPadded · filed 14 Aug 20262,640,214$34.3M+186,513+7.6%
ARMISTICE CAPITAL, LLCadded · filed 14 Aug 20262,198,000$28.6M+329,000+17.6%
ROYCE & ASSOCIATES LPadded · filed 14 Aug 20261,969,835$25.6M+440,884+28.8%
Broadfin Holdings LLCreduced · filed 14 Aug 20261,818,533$23.7M-250,800−12.1%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20261,694,716$22.0M-32,104−1.9%
WEBER CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20261,356,602$17.6M-16,547−1.2%
Nuveen, LLCreduced · filed 11 Aug 20261,199,358$15.6M-16,807−1.4%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,020,658$13.3M+35,235+3.6%
31 Mar 2023 – 30 Jun 2026
118137156Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Warren Nighan Jr. Company insiderSVP Quality and Regulatory · last 30 Jul 20262 · 2
Chad Thomas Campbell Company insiderSVP/GM, Vascular Access · last 22 Jul 20260 · 1
James C. Clemmer Company insiderPresident and CEO · last 22 Jul 20269 · 0
Laura Piccinini Company insiderSVP International · last 22 Jul 20260 · 0
Stephen A. Trowbridge Company insiderEVP and CFO · last 22 Jul 20265 · 2
Lawrence T. Weiss Company insiderSVP, Chief Legal Officer · last 16 Jul 20261 · 0
Eileen O'Shea Auen Company insiderDirector · last 15 Jul 20260 · 0
Howard W. Donnelly Company insiderDirector · last 15 Jul 20263 · 1
Jan Stern Reed Company insiderDirector · last 15 Jul 20261 · 0
Karen A. Licitra Company insiderDirector · last 15 Jul 20260 · 0
Lorinda Burgess Company insiderDirector · last 15 Jul 20260 · 0
Michael E. Tarnoff Company insiderDirector · last 15 Jul 20260 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2026 · to 31 May 202654.6%
Operating profit marginFY 2026 · to 31 May 2026-12.5%
Free cash flow marginFY 2026 · to 31 May 20260.2%
Return on capital employedFY 2026 · to 31 May 2026-20.7%
Research spendFY 2026 · to 31 May 20269.2%
Share count trendFY 2026 · to 10 Jul 2026-0.9%
Cash and equivalentsFY 2026 · to 31 May 2026$53.9M
Free cash flowFY 2026 · to 31 May 2026$508K

Analyst forecasts

No analyst forecasts yet.